WSJ
15 Jul 2026, 00:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
What the story claims
1 claim · each scored for market impact
Eli Lilly has not yet established a major presence in the obesity pill market. — Failure to diversify delivery methods beyond injectables could limit long-term market share and create openings for competitors.
-0.30Which stocks this story touches
The company is noted for failing to make a major dent in the pill market despite leading in obesity shots.
Continue reading
6 related stories
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
3h ago
